Please ensure Javascript is enabled for purposes of website accessibility

Why Lexicon Pharmaceuticals Skyrocketed 17% Today

By Todd Campbell – Sep 9, 2016 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Phase 3 data for a key drug for use in type 1 diabetes sent shares soaring.

Image source: Getty Images.

What happened

After announcing phase 3 data from a type 1 diabetes trial, shares in Lexicon Pharmaceuticals (LXRX -6.91%) jumped 16.85% today.

So what

Lexicon Pharmaceuticals is studying the safety and efficacy of sotagliflozin, a novel therapy for diabetes that targets both SGLT1 and SGLT2 for the first time.

Drugs that target SGLT2 independently of SGLT1 are already available, and they're quickly becoming top sellers, but the FDA has not yet approved any drug that inhibits the activity of both pathways at once. SGLT2 inhibitors improve glycemic control by blocking glucose absorption in the kidneys, while SGLT1 inhibitors play a similar role in the gastrointestinal tract. 

In a phase 3 trial enrolling 793 type 1 diabetes patients, sotagliflozin:

  • Met its primary endpoint of statistically reducing HbA1c at week 24 on a background of optimized insulin.
  • Showed that patients treated with a daily dose of 200 mg of it experienced an average reduction in HbA1c from baseline of 0.43% versus a 0.08% reduction for placebo (p<0.001). Patients receiving 400 mg of sotagliflozin once daily experienced an average 0.49% reduction (p<0.001).

The phase 3 results are bullish not only for Lexicon Pharmaceuticals, but also for Sanofi SA (SNY -0.10%). In an attempt to help protect its diabetes market share from the loss of patent protection on its top-selling Lantus, Sanofi licensed ex-U.S. rights to sotagliflozin last year. Specifically, Lexicon Pharmaceuticals received an upfront payment of $300 million, and Sanofi agreed to pay up to $1.4 billion in milestones, plus double-digit royalties on net sales, to acquire ex-U.S. rights in type 1 patients and global rights in type 2 patients. 

Now what

The addressable patient population in type 1 diabetes is smaller than it is in type 2, but type 1 results may bode well for late-stage trials planned by Sanofi in type 2. A second type 1 study is expected to read out data soon, and if results back up today's findings, then this drug has a shot at becoming an important weapon in the battle against diabetes.

Lexicon Pharmaceuticals retained rights to co-promote sotagliflozin in the U.S. in type 1 diabetics, and Sanofi SA has the marketing clout to get this drug in patients' hands. Therefore, today's announcement is very intriguing.

On Nov. 30, Lexicon Pharmaceuticals expects an FDA decision on the approval of its first drug, telotristat etiprate, and if it's approved, this drug could begin generating meaningful revenue next year. In trials, it reduced symptoms, including diarrhea, caused by excess serotonin production by metastatic neuroendocrine tumors that have spread from the GI tract to organs. 

Overall, this stock is still risky because it's not generating product sales yet, but potential revenue from telotristat etiprate in 2017, a cash stockpile that's north of $425 million, and the potential to eventually launch a unique new drug for diabetes all make this stock worth considering.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. Like this article? Follow him on Twitter where he goes by the handle @ebcapital to see more articles like this. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$38.86 (-0.10%) $0.04
Lexicon Pharmaceuticals Stock Quote
Lexicon Pharmaceuticals
LXRX
$2.29 (-6.91%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
338%
 
S&P 500 Returns
108%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.